Default company panoramic image


Cernostics saves lives by developing and commercializing molecular diagnostic tests for cancer and cancer related disease

  • Stage Product In Development
  • Industry Biotechnology
  • Location Danville, PA, USA
  • Currency USD
  • Employees 4
  • Website

Company Summary

Cernostics develops new molecular diagnostic tests for the fight against cancer. Our first commercial test predicts risk for developing Esophageal Cancer in patients with Barrett's Esophagus. 6 million people world-wide have Barretts, and physicians have great difficulty determining which patients are at greatest risk for cancer. This leads to imprecise treatment and patient uncertainty in healthcare systems. Our test addresses these issues.


  • Default avatar
    Mike Hoerres, MS
    Chief Executive Officer

    Mr. Hoerres is a seasoned biotechnology professional with more than 20 years in the life science industry in a variety of sales, marketing, and business development roles; including commercial positions at Geisinger Health Systems, Stratagene, Affymetrix, Incyte Genomics, and Source MDx. Mike holds a BS in biochemistry of University of Wisconsin and a Master of Science in molecular immunology from San Diego State University.

  • Default avatar
    Rebecca Critchley-Thorne, Ph.D.
    Director, Biomarker & Dx Development

    Rebecca is responsible for the development of novel cancer in vitro diagnostics based on Cernostics’ proprietary Tissue Systems Pathology approach. She is a cancer immunologist with expertise in molecular and functional profiling of patient samples and was previously a Senior Scientist at Cellumen, Inc. in the Patient Sample Profiling Program, responsible for the collaborative project on breast cancer diagnostics with the Mayo Clinic.

  • Default avatar
    Bruce Campbell, MS
    Director, Imaging Informatics

    Mr. Campbell is responsible for the development of image analysis tools for tissue-based multiplexed fluorescence cancer diagnostic tests, development of image analysis rule sets for tissue segmentation and fluorescence biomarker feature extraction, classifier development, and statistical analysis. Mr. Campbell is an experienced software engineer with over ten years experience at companies such as Omnyx, Bioimagene, TissueInformatics, Eastman Kod


  • Default avatar
    Hamilton Brook Smith and Reynolds
    Default avatar
    Grossman, Yanik and Ford, LLP